Share on LinkedInShare on LinkedIn

ARTICLE · 25 APRIL 2017

CFTC Appoints James Mcdonald As Enforcement Director

Herbert Smith Freehills Kramer LLP
Herbert Smith Freehills Kramer LLP
Contributor
Herbert Smith Freehills Kramer LLP

Herbert Smith Freehills Kramer LLP

We have one of the largest Southeast Asia international law practices, working across the region...

View firm profile
Explore more from Herbert Smith Freehills Kramer LLP

Acting CFTC chairman J. Christopher Giancarlo announced the appointment of James McDonald as director of the agency's Enforcement Division.

United StatesCriminal Law
George Silfen
George Silfen
Ronald Feiman
Ronald Feiman
Author LinkedIn connections

Acting CFTC chairman J. Christopher Giancarlo announced the appointment of James McDonald as director of the agency's Enforcement Division. He was most recently a prosecutor in the Southern District of New York and brings a track record of pursuing white collar and other crimes. McDonald assumed the role at the agency on April 10.

Related News:
CFTCâ€"s Market Risk Advisory Committee announces agenda for April 25 public meeting - CFTC
Link To Article

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters

Read more about

Related Comparative Guides

See more popular content from

Article

DOJ Announces 2026 National Health Care Fraud Takedown: 455 Defendants Charged In $6.5 Billion Enforcement Action

The Department of Justice's 2026 National Health Care Fraud Takedown charged 455 defendants in connection with $6.5 billion in alleged fraud schemes, marking an unprecedented scale of enforcement action. This whole-of-government approach leverages advanced data analytics and international cooperation to combat healthcare fraud across Medicare, Medicaid, and other federal programs. The enforcement action demonstrates heightened scrutiny of providers, aggressive asset forfeiture, and a focus on cases involvin
United StatesCriminal Law
Benesch, Friedlander, Coplan & Aronoff LLP
Benesch, Friedlander, Coplan & Aronoff LLP
Article

2026 Mid-Year Update On DOJ Corporate And White Collar Enforcement

The Department of Justice has implemented its first-ever Department-wide Corporate Enforcement Policy, fundamentally reshaping how companies navigate voluntary self-disclosure, cooperation, and remediation across all criminal matters. This comprehensive mid-year analysis examines the new three-path framework, explores critical enforcement developments in FCPA, export controls, trade fraud, and healthcare, and reveals how recent resolutions signal both opportunities and heightened risks for corporate complia
United StatesCriminal Law
Sher Tremonte
Sher Tremonte
Article

Prediction Markets — Legitimate Trading Or Gambling?

The rapid expansion of online prediction markets has created a regulatory gray area where consumers can effectively wager on sporting events even in states that prohibit traditional sports betting. As platforms like Kalshi, Polymarket, and Robinhood argue their services constitute futures trading rather than gambling, state attorneys general and the CFTC are locked in legal battles over jurisdiction and consumer protection.
United StatesCriminal Law
Klemchuk
Klemchuk
Article

The State Of The World’s Whistleblower Laws, Protections, And Rewards

Whistleblower protection has evolved significantly since the UN Convention Against Corruption in 2003, yet the scope of protections and rewards varies dramatically across jurisdictions. From the robust reward systems in the United States and South Korea to the EU's protection-focused directive and emerging programs in Ghana, countries have taken vastly different approaches to encouraging and safeguarding those who expose wrongdoing.
United StatesCriminal Law
Miller Shah LLP
Miller Shah LLP
Article

2026 Sees China's Biotech Scene Continuing Its Ascent – But Could US Developments Mean Clouds On The Horizon?

In recent years, China's biotech scene has risen in prominence with its innovative R&D and promising pipelines commanding big pharma's attention. In this blog, we take a look at this trend, which sees China-related deals and investment continuing to flow, as well as the recent developments in the US, with draft legislation being proposed that seeks to impose restrictions which would impact transactions between US pharma companies and Chinese biotechs. 
GlobalFood, Drugs, Healthcare, Life Sciences
Herbert Smith Freehills Kramer LLP
Herbert Smith Freehills Kramer LLP